LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Inclusion criteria: * Male or female patients of at least 18 years of age * Histologically confirmed, adenocarcinoma of the lung, after failure of first line platinum-based chemotherapy. Exclusion criteria: * More than one prior line of chemotherapy (i.e., 2nd or 3rd line chemotherapy) for advanced and/or metastatic (stage III B or IV NSCLC) or recurrent disease. * Patients known to be positive for activating Epidermal Growth Factor Receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation * Previous therapy with other vascular endothelial growth factor (VEGF) or VEGFR inhibitors (other than bevacizumab) or docetaxel for the treatment of NSCLC at any time * Prior monotherapy with an EGFR inhibitor except as maintenance therapy